Sugi Predict

Sugi Predict / Compounds / SCHEMBL4550245

SCHEMBL4550245

SCHEMBL4550245

CC(=O)N1CCCC(CO)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.51
▸ NPC1 O15118 5/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ POLB P06746 1/20 0.51
▸ EPHX2 P34913 5/20 0.50
▸ LIPE Q05469 1/20 0.47
▸ GRM3 Q14832 3/20 0.46
▸ PKM P14618 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP4F2 P78329 1/20 0.40
▸ CYP4A11 Q02928 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21665823 1.00 RAB9A (0.51) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL20942599 1.00 RAB9A (0.51) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL8155198 0.88 NPC1 (0.40) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL16751025 0.88 NPC1 (0.40) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL13827623 0.88 NPC1 (0.40) RAB9ANPC1SMN1; SMN2POLBEPHX2
Biphenyl SCHEMBL27455040 0.86 CYP2D6 (0.56) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL19277073 0.85 AKR1C3 (0.47) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL22968160 0.85 AKR1C3 (0.47) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL14393689 0.85 AKR1C3 (0.47) RAB9ANPC1SMN1; SMN2POLBEPHX2
SCHEMBL12683452 0.85 CYP4F2 (0.40) RAB9ANPC1SMN1; SMN2POLBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2025-06-26 — — US disclosed
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 — — US disclosed
WO-2024026484-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026486-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2022148422-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEIGENE, LTD. (KY) 2022-07-14 — — WO disclosed
US-20160326108-A1 PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS BRISTOL MYERS SQUIBB CO (US) 2016-11-10 — — US disclosed
US-9458171-B2 Pyrrolidinyl sulfone RORγ modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-04 — — US disclosed
US-20150191483-A1 PYRROLIDINYL SULFONE RORGAMMA MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2015-07-09 — — US disclosed
US-8563540-B2 Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use GENENTECH, INC. (US) 2013-10-22 — — US disclosed
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 — — EP disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 — — US disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 — — US disclosed
US-20090054407-A1 Nitrogen-containing heterocyclic compound KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
US-20090054407-A1 Nitrogen-containing heterocyclic compound KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
US-20090042883-A1 ANTITUMOR AGENT KYOWA HAKKOKOGYO CO. (JP) 2009-02-12 — — US disclosed
US-20090042883-A1 ANTITUMOR AGENT KYOWA HAKKOKOGYO CO. (JP) 2009-02-12 — — US disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 — — US disclosed
EP-1852112-A1 ANTI-TUMOR AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-11-07 — — EP disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 — — US disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 RAB9A 1980/4885NPC1 3471/4885SMN1; SMN2 3657/4885
US-20090054407-A1 Nitrogen-containing heterocyclic compound NR4A1, NR5A2, PRMT8 RAB9A 2603/4885NPC1 1107/4885SMN1; SMN2 3395/4885
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P RAB9A 1598/4885NPC1 1079/4885SMN1; SMN2 4682/4885
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES IL1B, NLRP3, NLRP1 RAB9A 2608/4885NPC1 2567/4885SMN1; SMN2 4456/4885
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF KRAS, NRAS, G3BP1 RAB9A 67/4885NPC1 4202/4885SMN1; SMN2 1542/4885
US-20090042883-A1 ANTITUMOR AGENT MCL1, HDAC7, TP53 RAB9A 2761/4885NPC1 1842/4885SMN1; SMN2 3714/4885
US-20160326108-A1 PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS RORC, RORB, RORA RAB9A 1255/4885NPC1 2981/4885SMN1; SMN2 1758/4885
US-20150191483-A1 PYRROLIDINYL SULFONE RORGAMMA MODULATORS RORC, RORB, RORA RAB9A 872/4885NPC1 2694/4885SMN1; SMN2 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.